PALM BEACH, Florida,
November 17, 2016 /PRNewswire/ --
Biotech industry professionals have suggested that a significant
part of the biotech rally of late may be a direct result of Trump's
victory with a vague promise to reform the FDA and "put greater
focus on the need of patients for new and innovative medical
products." Biotech stocks with current and recent achievements in
the markets include: Cellectar Biosciences, Inc. (NASDAQ:
CLRB), Array BioPharma Inc. (NASDAQ: ARRY), Aurinia Pharmaceuticals
Inc. (NASDAQ: AUPH), Amarin Corporation plc (NASDAQ: AMRN) and
Abbott Laboratories (NYSE: ABT).
Cellectar Biosciences, Inc. (NASDAQ: CLRB), an
oncology-focused, clinical stage biotechnology company, today
announces that following the successful conjugation of multiple,
natural product cytotoxic molecules developed by Pierre Fabre to
Cellectar's PDC delivery platform, it has initiated in vivo studies
for a variety of solid tumors. Harnessing a selection of
linkers to attach the cytotoxic molecules to the PDC platform, the
company has constructed a series of novel compounds specifically
designed for improved tumor targeting. This research
collaboration falls under the company's CLR CTX programs, geared to
convert non-targeted cytotoxic agents into targeted cancer
treatments when combined with Cellectar's proprietary delivery
system. The drug's targeting enhancement is designed to
further improve efficacy and reduce adverse events.
Read the full Cellectar Biosciences (CLRB) Press Release at:
http://marketnewsupdates.com/news/clrb.html
As part of the Pierre Fabre research collaboration, Cellectar
has already completed a series of in vitro studies with the newly
created compounds, and is currently compiling early efficacy data.
Cellectar will then initiate additional in vitro and in vivo
studies in melanoma, lung, and colon cancers, as well as in
additional solid tumors.
"We are excited by the rapid advancement of these programs and
look forward to sharing data from our development work with Pierre
Fabre," said Jim Caruso, president
and CEO of Cellectar Biosciences. "This partnership is an
excellent example of the power of our business model, a
cost-efficient system with the potential to generate high-yielding
assets. In parallel, we continue to make significant progress
on our lead radiotherapeutic PDC, CLR 131 for the treatment of
relapsed/refractory multiple myeloma, including our ongoing Phase I
and our impending NCI-supported Phase II clinical trial in selected
hematologic malignancies."
In other Biotech market performances and developments of
note:
Array BioPharma Inc. (NASDAQ: ARRY) closed up slightly on
Wednesday closing at $7 trading over
5.42 Million shares by the market close. Array BioPharma
retains exclusive rights to binimetinib and encorafenib in the
U.S., Japan, Canada, Korea and Israel which was recently reported Binimetinib
plus encorafenib meets primary endpoint with statistically
significant advantage on median PFS of 14.9 months versus 7.3
months for vemurafenib monotherapy. Read more at
http://finance.yahoo.com/news/columbus-phase-3-study-results-160000344.html
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a clinical
stage biopharmaceutical company focused on the global immunology
market, on Wednesday highlighted additional findings from its
global Phase IIb AURA study of voclosporin in the treatment of
lupus nephritis (LN). The abstract was presented at the American
College of Rheumatology and Association of Rheumatology Health
Professionals (ACR/ARHP) Annual Meeting in Washington, D.C. during the Late-Breaking News
session on November 15, 2016.
Amarin Corporation plc (NASDAQ: AMRN) closed up at
$3.45 on Wednesday trading over 4.38
Million shares traded by the market close. AMRN this
week announced an oral presentation that was held at the American
Heart Association Scientific Sessions 2016, New Orleans on November
14, 2016 that further characterized the efficacy and safety
of Vascepa® (icosapent ethyl) in statin-treated women with
persistent high triglyceride levels.
Abbott Laboratories (NYSE: ABT) closed up
14 cents at $39.95 on Wednesday trading over 8.8 Million
shares traded by the market close. ABT announced this month
that the Ministry of Health, Labor and Welfare (MHLW) in
Japan has approved the company's
Absorb bioresorbable heart stent, making the first-of-its-kind
medical device commercially available to treat people in
Japan with coronary artery
disease. Absorb is the only fully dissolving heart stent
approved in Japan for the
treatment of heart disease, one of the leading causes of death in
Japan and worldwide. An estimated
1.73 million people in Japan
(population:127 million) have heart disease, and approximately 71.7
thousand people die each year from coronary artery disease, making
it the secondary leading cause of death in the country annually.
Worldwide, more than 7.4 million people die of heart disease each
year.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party
publisher and news dissemination service provider, which
disseminates electronic information through multiple online media
channels. MNU is NOT affiliated in any manner with any
company mentioned herein. MNU and its affiliated companies
are a news dissemination solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment
licenses and may NOT sell, offer to sell or offer to buy any
security. MNU's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to
be strictly informational and is NEVER to be construed or
interpreted as research material. All readers are strongly
urged to perform research and due diligence on their own and
consult a licensed financial professional before considering any
level of investing in stocks. All material included herein is
republished content and details which were previously disseminated
by the companies mentioned in this release. MNU is not liable
for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. For current
services performed MNU has been compensated one thousand
seven hundred dollars for news
coverage of the current press release issued by Cellectar
Biosciences, Inc. by a non-affiliated third party. MNU
HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and MNU undertakes no
obligation to update such statements.
Contact Information:
Media Contact email: info@marketnewsupdates.com
, +1-561-325-8757
SOURCE MarketNewsUpdates.com